Clinical Trials Browser

Phase 2/3 × INDUSTRY × Basal Cell Nevus Syndrome × Clear all

NCT03070691 2017-05-05

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Phase 2/3 Withdrawn

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell